1) Hill MD, Abramson FP : The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady─state. Clinical Pharmacokinetics 14 : 156─170, 1988
2) Mandelli M, Morselli PL, Nordio S, et al : Placental transfer of diazepam and its deposition in the newborn. Clinical Pharmacology and Therapeutics 17 : 564─572, 1975
3) Bachrach LK, Dibattisa D, Burrow GN, et al : Transplacental effects of 3,5─dimethyl─3’─isopropyl─L─thyronine on fetal hypothyroidism in primates. Endocrinology 112 : 2021─2024, 1983
4) Moore KL, Persaud TVN : The Developing Human. Clinically Oriented Embryology. 7th ed, Saunders, 2003
5) Lenz W, Knapp K : Thalidomid─Embryopathie. Dtsch Med Wochenschr 87 : 1232─1242, 1962
6) Lenz W, Knapp K : Thalidomide embryopathy. Arch Environm Health 5 : 14─19, 1962 Nowack E. Die sensible Phase bei der Thalidomid─Embryopathie. Humangenetik 1 : 516─536, 1965
7) Kreipe U : Missbildungen innerer Organe bei Thalidomideembryopathie. Arch Kinderheilk 176 : 33─61, 1967
8) Herbst AL, Ulfelder H, Poskanzer DC : Adenocarcinoma of the vagina : Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 284 : 878─881, 1971
9) Vermillion ST, Scardo JA, Lashus AG : The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 177 : 256─261, 1997
10) Klein KL, Scott WJ, Clark KE, et al : Indomethacin─placental transfer, cytotoxity and teratology in the rat. Am J Obstet Gynecol 141 : 448─452, 1981
11) Department of Health, Education, and Welfare(US), Food and Drug Adminstration. Labeling and prescription drug advertising : Content and format for labeling for human prescription drugs. Final rule. 21 CFR Parts 202─202. Fed Reg 44 : 37434, 1979
12) Briggs GG, Freeman RK, Yaffe SJ : Drugs in pregnancy and lactation. 6th ed, Lippincott Williams&Wilkins, Philadelphia, 2002
13) Robert E, Guibaud P : Maternal valproic acid and congenital neural tube defects. Lancet 2 : 937, 1983